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Chronic kidney disease involves renal inflammation,
interstitial fibrosis, and tubular and vascular atrophy.
Macrophages seem to foster all of these histomorphological
abnormalities, but their specific contributions remain
controversial. Recruited monocytes differentiate into
different tissue macrophage phenotypes, but current
classifications are largely based on in vitro studies that do
not adequately mirror tissue environments in vivo.
To overcome this limitation, we propose to classify tissue
macrophages according to their predominant roles in the
phases of wound healing tissue environments, that is,
inflammation, epithelial healing, mesenchymal healing,
and fibrolysis. In this review, we discuss the evidence on
respective macrophage phenotypes in renal pathology.
This view sheds light on several aspects of renal remodeling
in kidney disease: (1) renal infection or cell necrosis
induces proinflammatory ‘M1’ macrophages that exacerbate
renal cell damage, (2) uptake of apoptotic cells induces
anti-inflammatory ‘M2c/suppressor’ macrophages that
promote epithelial and vascular repair, (3) insufficient
vascular and epithelial healing despite abundant growth
factor secretion promotes profibrotic ‘M2a/wound healing’
macrophages that accelerate fibrogenesis, and (4)
theoretically, fibrolytic macrophages should exist and await
investigation.
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There is broad agreement that fibrosis often follows
inflammation and that both associate with a decline of renal
function in chronic kidney disease (CKD), but their causal
relationship remains under debate.1,2 It is noteworthy that
inflammation is a clinical term. Histologically, inflammatory
lesions usually involve leukocyte recruitment. However,
the presence of leukocytes in renal biopsies must not
necessarily indicate inflammation. This distinction has
become important because leukocytes with anti-inflamma-
tory or profibrotic phenotypes are increasingly recognized
like regulatory T cells, fibrocytes, alternatively activated
macrophages, or myeloid-derived suppressor cells (MDSCs).3
The ongoing debate to what extent interstitial fibrosis on its
own just accompanies or actively promotes progressive CKD
will benefit from considering inflammatory tissue damage,
insufficient epithelial healing, and mesenchymal healing as
separate pathophysiological entities that altogether make up
the histopathological abnormalities in CKD. In this review,
we discuss the evolving evidence on the impact of distinct
macrophage phenotypes on ‘inflammation’, ‘epithelial heal-
ing’, ‘mesenchymal healing’, and the ‘resolution of fibrosis’.
Along the discussion, we learn how these distinct and
evolutionary conserved danger defense programs involve the
differentiation of recruited monocyte into different tissue
macrophage phenotypes that amplify their surrounding tissue
environment, a process that often leads to end-stage renal
disease, although intended to maintain tissue homeostasis.
Healing of tissue damage is as ancient as the evolution
of the metazoa.4 In primitive organisms, healing is mostly
complete without scarring, because of the high regeneratory
capacity of epithelia from their progenitor cells. This
functional property is limited in complex tissues of higher
organisms including the skin, although rapid and scarless
healing is partially maintained at embryonic and fetal stages
of development.5,6 Healing of mammalian skin wounds is
often taken as a general model to describe the serial danger
response programs that are involved in the healing process
(Table 1); that is, (1) clotting to avoid fatal blood loss, (2)
inflammation and (3) reepithelialization to avoid fatal sepsis,
(4) fibrosis to limit wound surface and to endure the injured
tissue, and (5) resolution of the fibrous matrix resulting
in the smallest possible scar area necessary.6,7 Macrophages
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contribute to stages 2–5 of the wound healing process
(Table 2),8 and we need to anticipate that their functional
heterogeneity is the result of different tissue environments at
each of these stages. At the early inflammatory stage, pro-
inflammatory macrophages produce multiple cytokine-,
lipid-, and oxygen-derived mediators that support neutro-
phils in direct pathogen killing (for example, by the release
of reactive oxygen species), and indirectly by activating
the tissue’s innate host defense (cytokine release) and by
recruiting additional immune cells (chemokine release).
Although inflammation protects from sepsis, its related
mediators limit the capacity for epithelial healing as
documented by an accelerated reepithelialization of sterile
wounds in PU.1-deficient mice that lack neutrophils and
macrophages, or in MyD88-deficient mice that largely lack
innate immune responses.9–11 This is because the killing effect
of reactive oxygen species or tumor necrosis factor (TNF) is
not only limited to pathogens but also promotes cell cycle
arrest or apoptosis in epithelial and endothelial cells.12 In
chronic wounds, macrophage iron overloading maintains
the proinflammatory macrophage phenotype that continues
to damage tissue cells.13 Interestingly, this process promotes
fibroblast senescence rather than proliferation, arguing
against the concept that inflammation per se is a driver
of fibrogenesis. In fact, chronic (leg) ulcers, such as those in
pyoderma grangraenosum, are associated with loss of tissue
rather than with excessive fibrosis. In contrast, when
inflammation is only transient, such as in acute and sterile
wounds, clearing apoptotic neutrophils induce macrophages
that have the potential to suppress the inflammatory
response together with other immunosuppressive lympho-
cytes.8 To reiterate this point, leukocytes in injured tissues
must, therefore, not necessarily indicate ongoing ‘inflamma-
tion’. In addition, profibrotic macrophages promote fibro-
blast proliferation and fibrogenesis in the fourth stage of
wound healing because they secrete large amounts of tumor
growth factor-b (TGF-b) and other profibrotic cytokines.
At the resolution stage, macrophages promote the clearance
of unnecessary extracellular matrix (ECM), referred to as
fibrolysis. Thus, from the perspective of wound healing, at
least four different types of macrophages with predominant
functional phenotypes should exist: proinflammatory macro-
phages, anti-inflammatory macrophages, profibrotic macro-
phages, and fibrolytic macrophages (Figure 1).
CLASSIFYING MACROPHAGE PHENOTYPES
How can we identify different macrophage phenotypes? The
functional heterogeneity of tubular epithelial cells is evident
by their unique structural appearance on light microscopy.
Phenotypic changes of podocytes require electron micros-
copy to image their structural rearrangement. In contrast, the
phenotypes of leukocytes can only reliably be charac-
terized by functional assays such as cytokine release
profiles or by assessing their surface marker expression by
flow cytometry. For example, these two methodological
approaches have enormously expanded our knowledge about
T-cell subtypes and how these promote different outcomes
of kidney disease.14,15 Similarly, functional assays and flow
cytometry are now increasingly used to unravel the functional
contribution of heterogeneous macrophage populations.16,17
For example, distinct surface markers allow to distinguish
circulating monocyte populations, as well as different tissue
macrophage phenotypes, although different markers must be
considered when studying mouse or human macrophages
(Table 2). A detailed discussion of classifying macrophages by
their surface marker expression profiles has been provided
elsewhere.18 An unsolved problem, however, is the incon-
sistency between in vitro macrophage studies and the
heterogeneity of tissue macrophages in vivo, which relates to
their phenotype plasticity in complex microenvironments.17
For example, in vitro studies have dissected classically
activated M1 macrophages and alternatively activated M2a,
M2b, and M2c macrophages according to their phenotypes
upon stimulation with defined stimuli.16,17,19 This working
model raised a lot of interest on macrophage heterogeneity,
but it has become clear that complex tissue environments are
not adequately mirrored by the M1/M2 paradigm. In the
following, we intend to refine the M1/M2 macrophage-
working model in view of the aforementioned putative
macrophage phenotypes that occur during the different
phases of wound healing, and we will discuss how they might
contribute to renal inflammation and fibrosis.
PROINFLAMMATORY MACROPHAGES
Acute tissue injury triggers a rapid influx of neutrophils that
is soon followed by an increased adhesion of circulating
monocytes to activated endothelial surfaces and their subse-
quent extravasation into interstitial compartments.20 At sites
of acute tissue injuries, the interstitial microenvironment is
Table 1 |Macrophages contribute to danger control and (dermal) wound healing
Danger control program Time frame Functional importance Macrophage contribution Side effects
Clotting Minutes Prevents fatal bleeding — —
Inflammation Hours–days Prevents fatal sepsis Pathogen killing, pathogen phagocytosis,
production of proinflammatory mediators
Collateral tissue
damage
Epithelial healing Days–weeks Prevents sepsis and
dysfunction
Secretion of anti-inflammatory and
growth factors
Epithelial
hyperplasia
Mesenchymal healing Weeks–months Tissue stability and endurance Secretion of profibrotic mediators Fibrosis/sclerosis
Fibrolysis Months Tissue stability with smallest
possible scar
Secretion of fibrolytic enzymes and
ECM clearance
Tissue instability?
Abbreviation: ECM, extracellular matrix.
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dominated by danger signals released from necrotic cells
(damage-associated molecular patterns (DAMPs)), such as
HMGB1, ATP, uric acid, or hypomethylated DNA.21,22
Erythrocyte-derived iron serves as an important DAMP in
skin wounds.13 External surfaces of the skin, gut, or the
respiratory tract are exposed to pathogens that release
pathogen-associated molecular patterns (PAMPs) that have
an identical potential to activate Toll-like and other innate
pattern recognition receptors on leukocytes and parenchymal
cells of the affected tissue (Figure 1). The same immuno-
stimulatory responses occurs inside the kidney, although a
PAMP contribution is less frequent.21,23,24 Toll-like receptor
(TLR) activation of the transmigrated monocyte requires
interferon-related factor (IRF)5 for full activation of NF-kB
signaling and the secretion of proinflammatory cytokines/
chemokines, reactive oxygen species, and other proinflam-
matory mediators that define a proinflammatory macro-
phage phenotype (Figure 2).25 Interferon-g, secreted by Th1
T cells and natural killer cells, or granulocyte-macrophage
colony-stimulating factor, are major components of the
cytokine microenvironment and further promote this
inflammatory tissue macrophage phenotype, as documented
for lupus nephritis, allograft rejection, or crescentic glomer-
ulonephritis.26–28 Proinflammatory macrophages release
matrix metalloproteases (MMPs) to enable their migration
through basement membranes and interstitial ECM
networks, but the resulting small ECM peptides themselves
can function as immunostimulatory DAMPs via TLRs and
maintain the proinflammatory macrophage phenotype.29
The secretory profile of inflammatory macrophages
mirrors to what has been classified as an ‘M1’ macrophage
by in vitro stimulation with lipopolysaccharide and other
microbial products (Table 3).19 It is intriguing to speculate
that the predominance of this bactericidal macrophage
phenotype in early phases of tissue injury has been positively
selected throughout evolution for host defense against
pathogens, an important and potentially life-saving danger
response element that outweighs the collateral tissue damage
that occurs because of the unspecific toxicity of the secreted
mediators. However, the sterile kidney mostly suffers from
proinflammatory macrophages infiltrates. For example, pro-
inflammatory macrophages release large amounts of TNF,
Table 2 | Surface marker expression of distinct monocytic cells in mice and humans
Macrophage-dendritic
cell progenitors Blood monocytes Tissue macrophages Fibrocytes
Function
Regulating
M/DC pool
Macrophage/DC
progenitor cells
Proinflam-
matory
Anti-
inflammatory Profibrotic Fibrolytic
Fibroblast
precursor
Macrophage/
DC precursor
M1 M2c M2a? ?
Transcription
factor
PU.1/IRF8 PU.1/IRF8 IRF5 IRF4/STAT3 IRF4/STAT6 ?
Mouse
markers
Lin-CX3CR1+
CD11b
CD115/
CSF-R+
CD117/
ckit+
CD135/
Flk2(Flt3)+
GR1+/
Ly6Chi CX3CR1lo
CCR2+
CD62L
(L-selectin)+
7/4+
CD115 (CSF-R)+
CD11b+F4/80
+CD68+
Ly6Chi
CCR2+
CX3CR1
MHCII+
CD86+
CD16/32+
Ly6Clo
CCR2-CX3CR1hi
MHCIIlo
CD163+
MR(CD206)+
SLAM+
IL-4R/
IL-10R
Ly6C/
CCR2+
CX3CR1+
MHCII+
CD23+
MSR1
(CS204)+
MR (CD206)+
Dectin-1+
DC-SIGN+
DCIR/DCL-1+
MGL1/2 (CD301a/b)+
IL-4R
? CD45+/mi
CD11b+
CD16/32+
MHCIIlo
CD115
CD34
CXCR4
CollagenI,Col. III+
Vimentin+
Fibronectin+
Human
markers
CD14hi
CD16- CX3CR1lo
CCR1+
CCR2+
CD62L
(L-selectin)hi
CD115 (CSF-R)+
CD11b+CD68+
CD14+
CD16+
MHCII+
CCR2+
CD14+
MHCIIlo
CD163+
MR(CD206)+
GPR105
RAGE
Integrin aVb3
IL-4R/
IL-10R
MHCII+
CD23+
MSR1
(CD204)+
MR (CD206)+
Dectin-1+
DC-SIGN+
DCIR and DCL-1+
CLEC10A+
GPR86, 105, P2Y12+
IL-4R
CD45+
CD14+/
CD16
CCR7+
CXCR4+
CD34+
MMP9hi
CollagenI+
Fibronectin+
CD45RO+ 25F9+
S100A8/A9+
Abbreviations: CCR, chemokine receptor; CLEC10A, C-type lectin domain family 10 member A; CSF-R, colony-stimulating factor receptor; DC, dendritic cell; DCIR, DC
immunoreceptor; DCL-1, DC ligand 1; DC-SIGN, Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin; IRF, interferon-related factor; MDP,
macrophage-dendritic cell progenitors; MGL, macrophage galactose type C-type lectin; MMP, matrix metalloprotease; MSR1, macrophage scavenger receptor 1; RAGE,
advanced glycosylation end product-specific receptor.
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a cytokine with two major biological functions. First, TNF
has an autocrine/paracrine effect on macrophage activation.
Second, the proapoptotic effects of TNF limit the survival of
activated immune cells30 but, as a side-effect, also induces
activation and apoptosis of renal parenchymal cells such as
vascular endothelial cells, tubular epithelial cells, and podo-
cytes that all express TNF receptors.31–34 As such, extra/
intrarenal infections or renal cell necrosis in AKI create
a DAMP(PAMP)-rich intrarenal microenvironment that
promotes differentiation of arriving monocytes toward the
proinflammatory phenotype, further amplifying intra-
renal inflammation and loss of renal parenchymal cells, for
example in anti-GBM glomerulonephritis,35 lupus nephritis,36–41
antigen-induced immune complex glomerulonephritis,42 renal
allograft injury,43 ischemia–reperfusion injury,44–46 and adria-
mycin nephropathy.47
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Figure 1 |Model on how renal microenvironments determine
macrophage phenotypes. Acute renal injury is often associated
with renal cell necrosis, which releases damage- and/or pathogen-
associated molecular patterns (DAMP/PAMP) that trigger the
release of proinflammatory cytokines. This environment drives
macrophage polarization toward the M1-like proinflammatory
macrophage phenotype. Subacute or chronic kidney injuries are
more often affected by renal cell apoptosis, where pentraxin-
mediated phagocytosis of apoptotic cells and homeostatic or
anti-inflammatory mediators rather promote macrophage
polarization toward an anti-inflammatory M2-like phenotype.
Once inflammation has ceased, the microenvironment is
dominated by growth factors that promote wound healing,
especially in conditions of incomplete or insufficient epithelial
repair. This environment drives macrophage polarization toward a
profibrotic phenotype that contributes to growth factor secretion.
Theoretically, the ischemic environment of a fibrotic kidney is
largely devoid of cytokines and growth factors, and it will be
important to study whether fibrolytic macrophages that have the
potential to remove connective tissue from the kidney exist. It is
important to note that all four categories are arbitrary, and that
in vivo mixture variants in a patchy distribution will determine
non-homogenous histopathological lesions in chronic kidney
disease. This needs to be considered when attempting to
characterize macrophage phenotypes from renal biopsies. CTGF,
connective tissue growth factor; EGF, epithelial growth factor; IFN,
interferon; iNOS, inducible nitric oxide synthase; MCP, monocyte
chemotactic protein; MMP, matrix metalloprotease; MR, mannose
receptor; PDGF, platelet-derived growth factor; SR, scavenger
receptor.
Renal cell stress
Necrosis
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Fibrolysis
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IL-10
Fibrosis
TGF-β
IRF5 IRF4
Figure 2 |Working model for the macrophage-dependent
balance of renal inflammation and fibrosis. Triggers of renal
cell damage activate renal cells, which results in subsequent
activation of innate and potentially adaptive immunity. This
includes the recruitment of monocytes that will differentiate into
different macrophage phenotypes depending on the local tissue
environment. Microenvironmental factors include distinct
cytokines, chemokines, and the dominating type of cell death,
as well as pathogens. For example, pathogens and necrotic cells
release factors that activate Toll-like and other innate immune
receptors that drive macrophage polarization toward the ‘M1’
proinflammatory macrophage involving the signaling molecule
interferon-related factor (IRF)5. Proinflammatory macrophages
release large amounts of proinflammatory mediators including
tumor necrosis factor (TNF) and reactive oxygen species (ROS).
This causes tissue inflammation and additional renal cell damage
fueling into a vicious circle of renal inflammation and
parenchymal loss leading to renal atrophy. In contrast, the
phagocytic uptake of apoptotic cells and other anti-inflammatory
signals favor macrophage polarization toward anti-inflammatory
or profibrotic ‘M2’ phenotypes involving the transcription factor
IRF4. Such macrophages release anti-inflammatory mediators
such as interleukin (IL)-10, which have the potential to suppress
renal inflammation. Others predominantly secrete growth factors
and profibrotic cytokines such as tumor growth factor (TGF)-b,
which further suppress inflammation and promote renal fibrosis.
Whether fibrolytic macrophages exist and from which antecessor
they develop remains speculative to date.
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Although clodronate liposome- or diphtheria toxin-
mediated macrophage ablation studies do not allow to
conclude on the functional contributions of only proinflam-
matory macrophages, some interventions are rather specific for
this macrophage phenotype.48,49 For example, Met-Rantes and
AOP-Rantes, two mutant chemokines, rather reduced glome-
rular macrophage numbers but activated those macrophages
that reached the glomerulus, which was sufficient to aggravate
antigen-induced glomerulonephritis.50 In addition, activated
monocytes express the chemokine receptor CCR2, which
mediates their recruitment to sites of monocyte chemoattrac-
tant protein-1/chemokine ligand (CCL) 2 expression.19,51
Blockade of either monocyte chemoattractant protein-1/
chemokine ligand 2 or CCR2 substantially reduces the number
of proinflammatory macrophages in inflamed tissues, an effect
that was shown to reduce immunopathology in a large number
of inflammatory kidney disease models.52,53 Furthermore, renal
ischemia–reperfusion models allow to distinguish the phases of
renal damage and repair. A recent study clearly demonstrated
that the early influx of proinflammatory M1 macrophages
largely determine acute kidney injury, for example, by early
clodronate depletion of macrophages and transfer of ex vivo
primed M1 macrophages.46 It has been proposed that
proinflammatory macrophages directly promote renal fibro-
sis,54 but DAMP/PAMP exposure does not activate macro-
phages (nor even fibroblasts) to secrete profibrotic cytokines
such as TGF-b1 (H-J Anders and M Ryu, unpublished data). In
addition, non-inflammatory models of renal fibrosis,
such as Alport nephropathy, do not benefit from mono-
cyte chemoattractant protein-1/chemokine ligand 2 blockade,
indicating that proinflammatory macrophages are of minor
importance in certain types of renal fibrosis.55 Furthermore,
and as mentioned before, proinflammatory macrophages
rather induce fibroblast senescence.13 Together, infectious
organisms and/or cell necrosis release PAMPs and DAMPs
that create a distinct tissue microenvironment that activates
infiltrating monocytes via TLRs and other innate pattern
recognition receptors towards a proinflammatory pheno-
type. Enhanced pathogen killing causes collateral tissue
damage, for example, via release of reactive oxygen species,
MMPs, and proapoptotic cytokines. Proinflammatory
macrophages rather suppress epithelial repair or fibroblast
proliferation. As a consequence, reducing activated proinflam-
matory macrophages can prevent immunopathology in injured
kidneys.
ANTI-INFLAMMATORY MACROPHAGES
Many types of kidney diseases are devoid of infection or renal
cell necrosis, and the intrarenal microenvironment will rather
be dominated by renal cell apoptosis. Apoptotic cell death is
fundamentally different from necrotic cell death because
apoptosis (but not necrosis) is a central element of home-
ostasis.56 Phagocytic clearance of apoptotic cells by macro-
phages is an important physiological element of tissue
homeostasis and immune tolerance; hence, it is not associated
with immune activation and rather stimulates epithelial
healing.57,58 In fact, apoptosis of activated neutrophils and
T cells is a mechanism that prevents inappropriate or
persistent immunopathology. When apoptosis occurs in the
context of infection, coexposure of TLR agonists and
apoptotic cells adds onto macrophage activation in an M1-
like manner; however, this effect is short-lived and turns into
sustained TGF-b release.59 When pathogens or necrotic cell
debris have been removed from tissues, the uptake of
apoptotic cells gradually promotes rather an anti-inflamma-
tory macrophage phenotype (Figure 1), as such macrophage
infiltration in acute kidney injury has been considered as a
‘clean-up crew’ for apoptotic neutrophils.45 Serum amyloid-P,
also named pentraxin-2, opsonizes apoptotic cells, which
further promotes the anti-inflammatory macrophage pheno-
type.60 Interestingly, this process must not necessarily
involve a signal for renal fibrosis; in fact, deactivating
macrophages with pentraxin-2 has rather antifibrotic effects
on the kidney.60,61 Immunosuppressive (‘regulatory’) T cells
further promote the polarization towards anti-inflammatory
macrophages via release of IL-10 and TGF-b.62 It is of note
that TGF-b has potent immunosuppressive effects and
should, therefore, not exclusively be taken as a profibrotic
cytokine.63 An integration of these different environmental
signals for the deactivation of the macrophage occurs at
the level of the transcription factor IRF4, which also functions
as an intracellular competitor of IRF5, and thereby blocks
TLR and IL-1R signaling (Figure 2).64–67 Evidence for a
functional role of anti-inflammatory macrophages for renal
healing responses comes from acute kidney injury studies
using the acute ischemia–reperfusion model. In the post-
ischemic kidney, M1 macrophages subsequently undergo a
phenotypic switch toward anti-inflammatory M2 macro-
phages that promote tubular repair, a process driven by
tubular epithelial cell-derived factors, as well as by the
uptake of apoptotic neutrophils.46,68 Lack of IRF4 enables
Table 3 |Macrophage phenotypes defined by in vitro studies
Phentoype Stimulation Expression/secretion
Classical activation (M1) IFN-g, TNF-a, LPS, GM-CSF IL-1, IL-12, IL-23, TNF-a, ROS, NO, iNOS, MHCIIhi, IL1-R
Alternative activation (M2a) IL-4 or IL-13 Fibronectin, arginase-1, mannose and scavenger receptor, decoy IL-1R11,
FIZZ1, YM-1
Immunoregulation (M2b) Immune complexesþ LPS IL-1, IL-6, TNF-a, MHCIIhi, IL-10hi, IL-12lo
Deactivation (M2c) Glucocorticoids, IL-10, TGF-b IL-10, TGF-b, CD150, mannose receptor
Abbreviations: GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; iNOS, inducible nitric oxide synthetase; LPS, lipopolysaccharide;
MHC, major histocompatibility complex; NO, nitric oxide; ROS, reactive oxygen species; TGF-b, tumor growth factor b; TNF, tumor necrosis factor.
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macrophages to undergo this M1–M2 phenotype switch,65
and therefore the aggravated postischemic inflammation
induces acute tubular necrosis (without any evidence for
renal fibrosis).32 In addition, direct IL-4/IL-10 treatment or
genetically modified or transfused IL-10-stimulated macro-
phages is able to resolve renal inflammation and injury.69–73
Steroid-based treatments seem to suppress renal inflamma-
tion by inducing anti-inflammatory macrophages.74 Hence,
a macrophage phenotype that counteracts renal inflammation
promotes epithelial healing and preserves renal function,75
a process that regulates the balance of renal inflammation
and (tubular) epithelial healing, and not necessarily fibro-
genesis, in a direct way.
Macrophage classifications that are based on in vitro
studies have not yet integrated apoptotic cells as a stimulus of
differentiation, but the phenotype of cultured macrophages
stimulated with IL-10 and TGF-b (or glucocorticoids),
referred to as the M2c type, shares similarities with anti-
inflammatory macrophages (Table 3).19,70–73,76,77 These cells
themselves produce large amounts of IL-10 that should
mimic the in vivo situation and mirror the resolution of
inflammation.17 A conceptual proof for this concept was
provided by Wang et al.,72 who observed an attenuation
of adriamycin-induced renal pathology upon injection of
M2 macrophages that had been primed ex vivo with IL-4 and
IL-13. This aspect is shared by a group of tumor-associated
macrophages that mediate immunosuppression in tumor
environments.78–80 In addition, MDSCs produce immune
suppressive factors such as arginase I or inducible nitric
oxidase synthase. The phenotype of MDSCs has been
identified as CD11bþGr1þ in mice, and as LIN-HLA-
DR-CD33þ or CD11bþCD14CD33þ in humans.
MDSCs can be distinguished from tumor-associated macro-
phages by the high expression of Gr-1 and low expression of
F4/80.3 Together, a microenvironment dominated by cell
apoptosis and anti-inflammatory cytokines can deactivate
proinflammatory macrophages or directly promote the
differentiation into anti-inflammatory macrophages. It is
noteworthy that anti-inflammatory macrophages amplify
their anti-inflammatory environment in the same way as M1
macrophages amplify inflammatory environments. As such,
anti-inflammatory macrophages abate many toxic and
proapoptotic factors that limit efficient epithelial healing.
Therefore, if inflammation is only short-term and transient,
as in mild to moderate toxic or ischemia–reperfusion injury
of the kidney, anti-inflammatory macrophages will enhance
tubular reepithelialization. This process, if not hampered by
persistent or recurrent injuries, can regenerate, for example,
tubular structure and function, without significant interstitial
fibrosis.
PROFIBROTIC MACROPHAGES/FIBROCYTES
Macrophage depletion almost always reduced interstitial
fibrosis, and therefore it is concluded that macrophages are
profibrotic.1,2,54,81 Given macrophage heterogeneity, it is now
getting clear that anti-inflammatory macrophages do not
necessarily trigger fibrogenesis directly, and that proinflam-
matory macrophages rather promote renal cell death. In view
of the wound healing concept, inflammation and epithelial
healing are primary danger response programs. In contrast,
fibrosis is rather a second-line danger response program that
only becomes relevant when epithelial healing is insufficient,
incomplete, or persistently suppressed by ongoing injury and
inflammation.6,7 In fact, epithelial cells and non-inflamma-
tory (and not proinflammatory) macrophages are major
sources of profibrotic cytokines that drive fibroblast
growth.82 Although platelet-derived growth factors (such as
PDGF) and certain proinflammatory cytokines, such as IL-6,
promote regenerative growth from the earliest stages of tissue
damage, the renal microenvironment becomes dominated by
growth factors released from damaged epithelia only with
some delay (Figure 1).83 In vitro cytokines such as IL-4 and
IL-13, for example, released from basophils and Th2 T cells,
further promote a macrophage phenotype that predomi-
nantly releases fibronectin and other ECM molecules.19 These
cells have been classified as M2a macrophages (Table 3). To
what extent, or if at all, anti-inflammatory and profibrotic
macrophages can be clearly distinguished in vivo remains
unclear, and it appears likely that macrophage plasticity
creates a mixture or continuous variant shifts in CKD lesions.
The balance of these different M2 macrophages and their
contribution to renal fibrosis deserves further study. How-
ever, ex vivo IL-4/IL-13-primed and injected macrophages
displayed a stable phenotype in adriamycin-induced fibro-
sis.72 Nevertheless, M2 macrophages predominate in fibrotic
lesions, and it is intriguing to speculate that paradigmatic
fibrotic kidney diseases such as Alport syndrome, Orellanus
syndrome, Balkan nephropathy, Chinese herb nephropathy,
or chronic allograft failure are associated with this profibrotic
macrophage phenotype (Figure 3). First evidence comes from
a study using collagen 4A3-deficient mice with Alport
syndrome. Progression of Alport syndrome in these mice is
associated with significant M2 macrophage infiltrates.31 As
such, blocking the monocyte chemoattractant protein-1/
CCR2 axis, an intervention that ameliorated many other
murine CKD models,84 was ineffective in Alport mice
because only proinflammatory, but not anti-inflammatory
or profibrotic (M2), macrophages express CCR2 (ref. 55). In
contrast, blocking the chemokine receptor CCR1, which is
present on M2 macrophages, reduced interstitial macro-
phages and fibrosis and prolonged survival of collagen 4A3-
deficient mice.85 The profibrotic role of CCR1þ interstitial
macrophages was also confirmed in diabetic nephropathy of
db/db mice, adriamycin-induced nephropathy, and after
unilateral ureteral obstruction.86–89 However, CCR1 may
not be selectively expressed by M2 macrophages; therefore,
additional work is necessary to dissect the functional
significance of this cell type. In contrast, mice deficient for
the chemokine receptor CCR5 cannot activate macrophages
through proinflammatory chemokines such as CCL3-5,
CCL8, and CCL14. These mice are not generally protected
from renal inflammation;90 however, when wild-type kidneys
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are transplanted into Ccr5-deficient mice, the allograft
developed a profound interstitial fibrosis associated with
infiltrates of host M2 macrophages.91
Fibrocytes have been described as another profibrotic
myeloid cell type that shares phenotypic characteristics
between monocyte/macrophages and fibroblasts.92 Fibrocytes
are fibroblast-committed monocytes that can be distin-
guished in the intravascular compartment from mono-
cytes.92–94 Some authors demonstrated that fibrocytes
actively produce collagens once they enter sites of kidney
injury, conceptually similar to a bone marrow-derived
fibroblast progenitor cell.95,96 The quantitative significance
of this phenomenon remains under debate. For example,
green fluorescence protein lineage tracing using the collagen
1a1 promoter found this to be a rather rare phenomenon
during renal fibrogenesis upon ureter obstruction in mice.97
Together, renal fibrosis may not be directly triggered by
proinflammatory macrophages but rather indirectly by
(inflammation-mediated) insufficient epithelial healing or
by profibrotic (‘M2’) macrophages and fibrocytes.
FIBROLYTIC MACROPHAGES
The evidence in the field of renal fibrosis is dominated by the
broad use of the irreversible unilateral ureteral obstruction
model, which is progressive in nature and does not allow
studying a potential resolution of interstitial fibrosis. How-
ever, understanding the mechanisms of reversible fibrosis
may offer novel perspectives for progressive CKD. It is
important to note that fibrosis is potentially reversible, for
example, in the last stage of dermal wound healing or after
toxic liver injury. For example, the proper reconstruction of
the epithelial compartment induces an orchestrated fibrolytic
program that has the potential to an almost complete reversal
of advanced interstitial fibrosis.98 Macrophage depletion in
the late phase of toxic liver fibrosis delayed the clearance of
liver scars,99 a process associated with MMP13 release by
scar-associated macrophages.100 Principally, the same fibro-
lytic program should operate in fibrotic kidneys.101 Evidence
for this concept comes from reversible glomerulosclerosis of
patients with type I diabetes undergoing pancreas trans-
‘Non-inflammatory’ chronic disorders
→ Primary FSGS, Alport
Acute injuries that progress, if not controlled
→ RPGN, IN, allograft rejection  
Slowly progressive renal disorders
→ DN, HTN, smoldering IgAN/LN/MN, CAN  
Intermittent flares of chronic nephropathies
→ flares of IC-GN, transient infections  
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Figure 3 |Phase-dependent balance of renal inflammation
and fibrosis in kidney diseases. The balance of inflammation
and fibrosis varies over time and is different from the type and
persistence of the underlying trigger. (a) Acute and non-persistent
injuries generate a serial predominant involvement of
inflammation and fibrosis involving predominantly M1 and M2
macrophages, respectively, that is similar to the wound healing
stages of the skin. For example, acute tubular necrosis (ATN)
triggers a profound but short-lasting inflammation involving
early influx of neutrophils and proinflammatory macrophages.
Subsequently, anti-inflammatory macrophages predominate and
renal inflammation undergoes resolution. In ATN, fibrogenesis
remains usually mild and transient when the trigger does not
persist and provided that epithelial healing is able to rapidly
regenerate the tubular compartment. (b) In rapid-progressive
glomerulonephritis (RPGN), interstitial nephritis (IN) or allograft
rejection the inflammatory trigger is intense and persists.
Profibrotic macrophages represent a sub-population of all renal
macrophages that promote the mesenchymal healing and
scarring as a result of persistent inflammation and insufficient
epithelial repair. (c) In many chronic kidney diseases, anti-
inflammatory macrophages may represent the predominant
macrophage phenotype, but flares of the underlying autoimmune
process or intercurrent infections promote transient
differentiation toward proinflammatory macrophages. Therefore,
flares of systemic inflammation are often associated with transient
intrarenal inflammation and renal cell damage. This process may
subsequently activate profibrotic macrophages and promote
fibrosis, in particular, when epithelial repair is inappropriate.
IC-GN¼ immune complex glomerulonephritis. (d) Diseases such
as diabetic nephropathy (DN), hypertensive nephropathy (HTN),
or smoldering forms of IgA nephropathy (IgAN), lupus nephritis
(LN), membranous nephropathy (MN), and chronic allograft
nephropathy (CAN) involve a considerable but not overwhelming
degree of intrarenal inflammation. It is likely that proinflammatory
and profibrotic macrophages coexist in small numbers and drive
both inflammation-mediated loss of renal cells and fibrogenesis.
Proteinuria is a cofactor for intrarenal inflammation and chronic
kidney disease progression. (e) Genetic variants of renal cell
biology, such as in primary focal segmental glomerulosclerosis
(FSGS) or Alport syndrome, are associated with little inflammation,
and anti-inflammatory and/or profibrotic macrophages
predominate in the immune cell infiltrates that occur over time.
Therefore, sclerosis and fibrosis remain the predominant lesions,
although large-scale proteinuria may introduce an inflammation
component that adds onto the spectrum.
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plantation.102 Experimental and clinical studies document
the same for non-diabetic glomerulosclerosis treated for
prolonged periods with angiotensin conversion enzyme
inhibition.103,104 In addition, Zeisberg and Kalluri reported
in a series of studies that recombinant human BMP7 is capable
of regenerating severely abnormal kidney structures, including
the disappearance of robust renal fibrosis.105 Macrophages are
capable of digesting such ECM deposits by the secretion of
selected MMPs.101 MMPs have the potential to limit or reverse
fibrogenesis.106 It is therefore intriguing to speculate that a
macrophage subtype with predominant fibrolytic activity
exists in the ischemic environment of scar tissue, which has
the potential to digest ECM without concomitant secretion of
proinflammatory cytokines (Figure 1). Surface markers that
would allow to identify fibrolytic macrophages have not
yet been described, but it should be technically feasible to
isolate macrophages from non-inflammatory scarred skin or
kidneys to characterize their phenotypic characteristics.
Although the fibrolytic macrophage might be a rare guest
inside the kidney, it would be instrumental to learn more
about its potential to limit or to reduce renal fibrosis. It will be
important to study whether increased clearance of ECM from
the renal interstitium is of any functional benefit for renal
function or rather results in tissue disintegration or in even
faster shrinking kidneys. It has also become clear that
MMP-secreting macrophages can also contribute to renal
damage by degrading glomerular and tubular basement
membranes and subsequent epithelial atrophy.101,107 There-
fore, fibrolytic macrophages could also be basement mem-
brane-degrading macrophages that rather contribute to renal
atrophy. In fibrotic livers, however, transfer of bone marrow-
derived macrophages was shown to reverse hepatic fibrosis and
improve regeneration and function of the liver.108
FUTURE PERSPECTIVE AND DIRECTIONS FOR RESEARCH
It is now becoming clear that macrophages contribute to renal
pathology through functionally distinct phenotypes as recently
discovered for dendritic cells, B cells or T cells (Figure 2). A
deeper knowledge about their temporal or spatial distribution
in the kidney will certainly affect our understanding of renal
immunopathology like it changed upon the discovery of Th1,
Th2, Th17, and regulatory T cells.15 However, to assess
macrophage phenotypes is not yet as easy as with T cells. We
are still in need of better surface markers that allow a
convenient and distinctive identification of either phenotype by
immunostaining or fluorescence-activated cell sorting. Such
lineage-specific markers are needed to characterize the
temporal appearance of each phenotype in the different phases
of a single disease, as well as a comparison between different
diseases (Figure 3). Gene profiling is another approach to
determine the predominant macrophages, but it will always
represent only pooled kidney data.31,91 So far, expression
studies teach us that different macrophage subtypes coexist in
CKD. Determining the predominant macrophage phenotype
may be of prognostic value in terms of renal cell loss or fibrosis,
or might allow to choose either an anti-inflammatory or an
antifibrotic type of therapy. Lineage-specific markers will also
guide the development of lineage-specific therapeutic tools. A
selective neutralization of distinct macrophage phenotypes is
ultimately necessary to determine the functional role of each
macrophage type for kidney pathology. Although the current
evidence suggests that preventing early renal inflammation by
neutralizing proinflammatory macrophages is sufficient to
prevent renal atrophy and fibrosis, we must admit that this may
not apply to the treatment of non-inflammatory types of renal
fibrosis or late stages of kidney diseases where other
macrophage phenotypes predominate. Late-stage kidney dis-
ease might benefit from fibrolytic macrophages and hence we
would like to motivate the renal community to start efforts to
identify and characterize renal fibrolytic macrophages. This is
attractive from a scientific point of view, although it remains
controversial whether enhanced clearance of ECM from fibrotic
kidneys without restoring renal parenchymal cells can have any
beneficial impact on renal excretory function.1,81,109
SUMMARY AND CONCLUSIONS
Renal pathology is the result of different danger response
programs that evolutionally derive from host defense and
tissue repair upon injury. The sequence of danger response
programs that occur after skin injury (inflammation–epithe-
lial healing–mesenchymal healing–fibrolysis) has been posi-
tively selected throughout the evolution of multicellular
organisms. Kidney disease never created a selection pressure
to alter this effective danger response algorithm. Unique
macrophage phenotypes contribute to all stages of these
defense and repair programs; however, as the histomorphol-
ogical abnormalities in CKD are complex, it remains
technically difficult to dissect their presence in renal biopsies
or their functional contribution to single diseases. Given the
increasing knowledge about the plasticity of intrarenal
dendritic cells, it is most likely that spatially and temporarily
different microenvironments change the phenotype of
macrophages as necessary. Therefore, a renal biopsy only
displays a screenshot of dynamic processes not always pro-
viding an obvious clue to the underlying pathomechanisms.
For the sake of a conceptual advance and a refined working
hypothesis, we propose to classify macrophage phenotypes by
their functional characteristics as proinflammatory, anti-
inflammatory, profibrotic, and fibrolytic macrophages. This
classification does not entirely match with previous classifi-
cations, especially not with all aspects of the M1/M2
paradigm that is based on distinct in vitro culture conditions
that do not sufficiently mirror in vivo environments. But the
idea that the tissue microenvironments determine macro-
phage phenotypes allows us to intepret the present data in a
different way and to design better experiments in the future.
Much more work remains to be done to more clearly
define functionally important macrophage phenotypes in the
different stages of each kidney disease (Figure 3). However,
we are confident that three conclusions will survive future
discoveries: (1) blocking inflammatory macrophages protects
from renal immunopathology, (2) the progression of renal
922 Kidney International (2011) 80, 915–925
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fibrosis is associated with leukocyte infiltrates, which does
not necessarily implicate inflammation, and (3) renal fibrosis
develops rather as a result of insufficient epithelial and
vascular healing. Therefore, controlling renal inflammation
and promoting epithelial/vascular repair are probably the best
ways to target renal fibrosis and to maintain renal function.
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